The Study of Infliximab (CMAB008 and Remicade) in Healthy Subjects to Compare the PK and Safety
Status:
Completed
Trial end date:
2020-06-15
Target enrollment:
Participant gender:
Summary
A phase 1, Randomized, Double-blind, Parallel group, Sing-dose study to compare the
Pharmacokinetics and Safety of CMAB008 and Remicade in healthy subjects.